相关实验视频
Updated: Jul 28, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
在非酒精性脂肪肝炎中使用抗纤维素疗法:是时候采取以人为本的方法了
Paul N Brennan1,2, Ahmed M Elsharkawy3, Timothy J Kendall1,4
1Institute for Regeneration & Repair, University of Edinburgh, Edinburgh, UK.
非酒精性脂肪肝炎 (NASH) 治疗面临挑战,但结合疗法和精密医学等新方法为开发有效的抗纤维药物改善肝脏健康提供了希望.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
- 遗传学 遗传学 是一个
背景情况:
- 非酒精性脂肪肝炎 (NASH) 是导致末期肝病和肝移植的原因之一.
- 纤维化严重程度是NASH肝脏相关结果的主要预测因素.
- 目前用于NASH的抗纤维菌疗法尽管进行了众多临床试验,但取得了有限的成功.
研究的目的:
- 分析NASH药物治疗试验中抗纤维素作用不足的原因.
- 提出提高未来抗纤维素药物开发在NASH中的成功的策略.
主要方法:
- 审查目前的临床试验数据和NASH的药理方法.
- 整合多组数据,电子健康记录和现代药理学.
- 专注于了解NASH的病原和易感性.
主要成果:
- 在NASH药物治疗试验中,抗纤维素效应在很大程度上是令人失望的.
- 尽管面临挑战,但在了解NASH方面的进步为药物开发提供了新的途径.
结论:
- 在NASH抗纤维素治疗中,未来的成功可能取决于组合药物策略.
- 精准医学的方法针对纳什的基因修饰剂显示出有前途.
- 更好地了解NASH的发病性对于开发有效的治疗方法至关重要.
更多相关视频
04:14Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
相关概念视频
Atherosclerosis III: Management
Chronic Pancreatitis II: Collaborative Care
Assessment:
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Atherosclerosis IV: Nursing Management